Biotechnology and Health Sciences

Published by: Kowsar

Preparation and Characterization of Monoclonal Antibody Against Truncated Recombinant Nuclear Matrix Protein (NMP22)

Mahsa Faghihi 1 , Malihe Paknejad 2 , Mohammad Reza Sarookhani 1 , * , Sepideh Soukhtehzari 3 , Hamed Zare 4 , Hosein Gahremani 2 and Mohammad Javad Rasaee 3
Authors Information
1 Cellular and Molecular Research Center, Qazvin University of Medical Sciences, Qazvin, IR Iran
2 Department of Biochemistry, Faculty of Medical Sciences, Tehran University of Medical Sciences, Tehran, IR Iran
3 Department of Medical Biotechnology, School of Medical Sciences, Tarbiat Modares University, Tehran, IR Iran
4 Department of Pharmaceutical Biotechnology, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
Article information
  • Biotechnology and Health Sciences: February 2018, 5 (1); e34332
  • Published Online: May 24, 2016
  • Article Type: Research Article
  • Received: November 3, 2015
  • Revised: January 28, 2016
  • Accepted: February 21, 2016
  • DOI: 10.17795/bhs-34332

To Cite: Faghihi M, Paknejad M, Sarookhani M R, Soukhtehzari S, Zare H, et al. Preparation and Characterization of Monoclonal Antibody Against Truncated Recombinant Nuclear Matrix Protein (NMP22), Biotech Health Sci. 2018 ; 5(1):e34332. doi: 10.17795/bhs-34332.

Abstract
Copyright © 2016, Qazvin University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited
1. Background
2. Objectives
3. Materials and Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Aminian O, Saburi A, Mohseni H, Akbari H, Chavoshi F, Akbari H. Occupational risk of bladder cancer among Iranian male workers. Urol Ann. 2014;6(2):135-8. doi: 10.4103/0974-7796.130643. [PubMed: 24833825].
  • 2. Shakhssalim N, Hosseini SY, Basiri A, Eshrati B, Mazaheri M, Soleimanirahbar A. Prominent bladder cancer risk factors in Iran. Asian Pac J Cancer Prev. 2010;11(3):601-6. [PubMed: 21039023].
  • 3. Akbari ME, Hosseini SJ, Rezaee A, Hosseini MM, Rezaee I, Sheikhvatan M. Incidence of genitourinary cancers in the Islamic Republic of Iran: a survey in 2005. Asian Pac J Cancer Prev. 2008;9(4):549-52. [PubMed: 19256736].
  • 4. Murta-Nascimento C, Schmitz-Drager BJ, Zeegers MP, Steineck G, Kogevinas M, Real FX, et al. Epidemiology of urinary bladder cancer: from tumor development to patient's death. World J Urol. 2007;25(3):285-95. doi: 10.1007/s00345-007-0168-5. [PubMed: 17530260].
  • 5. Carlson RH. Use of nmp22 bladder cancer assay increases rate of detection of recurrence. Oncology Times. 2006;28(5):14-5.
  • 6. Proctor I, Stoeber K, Williams GH. Biomarkers in bladder cancer. Histopathology. 2010;57(1):1-13. doi: 10.1111/j.1365-2559.2010.03592.x. [PubMed: 20579130].
  • 7. Hwang TIS, Tsai TF, Juang GD, Yeh CH, Cheng YH, Chou KY. Application of the NMP22 test in the diagnosis of transitional cell carcinoma of the urinary bladder. Cell Biol. 2009;34:54-68.
  • 8. Halling KC, Kipp BR. Bladder cancer detection using FISH (UroVysion assay). Adv Anat Pathol. 2008;15(5):279-86. doi: 10.1097/PAP.0b013e3181832320. [PubMed: 18724101].
  • 9. Burchardt M, Burchardt T, Shabsigh A, De La Taille A, Benson MC, Sawczuk I. Current concepts in biomarker technology for bladder cancers. Clin Chem. 2000;46(5):595-605. [PubMed: 10794739].
  • 10. Parker J, Spiess PE. Current and emerging bladder cancer urinary biomarkers. ScientificWorldJournal. 2011;11:1103-12. doi: 10.1100/tsw.2011.104. [PubMed: 21623456].
  • 11. Tomasini JM, Konety BR. Urinary markers/cytology: what and when should a urologist use. Urol Clin North Am. 2013;40(2):165-73. doi: 10.1016/j.ucl.2013.01.015. [PubMed: 23540775].
  • 12. Chiong E, Gaston KE, Grossman HB. Urinary markers in screening patients with hematuria. World J Urol. 2008;26(1):25-30. doi: 10.1007/s00345-007-0229-9. [PubMed: 18060548].
  • 13. Zare H, Rajabibazl M, Rasooli I, Ebrahimizadeh W, Bakherad H, Ardakani LS, et al. Production of nanobodies against prostate-specific membrane antigen (PSMA) recognizing LnCaP cells. Int J Biol Markers. 2014;29(2):e169-79.
  • 14. Cattoretti G, Becker MH, Key G, Duchrow M, Schluter C, Galle J, et al. Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol. 1992;168(4):357-63. doi: 10.1002/path.1711680404. [PubMed: 1484317].
  • 15. Herzenberg LA, De Rosa SC. Monoclonal antibodies and the FACS: complementary tools for immunobiology and medicine. Immunol Today. 2000;21(8):383-90. [PubMed: 10916141].
  • 16. Farahnejad Z, Rasaee MJ, Moghadam MF, Paknejad M, Kashanian S, Rajabi M. Preparation and characterization of a monoclonal antibody against mannoprotein of Candida albicans. Hybridoma (Larchmt). 2005;24(3):146-51. doi: 10.1089/hyb.2005.24.146. [PubMed: 15943562].
  • 17. Abd El Gawad IA, Moussa HS, Nasr MI, El Gemae EH, Masooud AM, Ibrahim IK, et al. Comparative study of NMP-22, telomerase, and BTA in the detection of bladder cancer. J Egypt Natl Canc Inst. 2005;17(3):193-202. [PubMed: 16799657].
  • 18. Paknejad M, Rasaee MJ, Tehrani FK, Kashanian S, Mohagheghi MA, Omidfar K, et al. Production of monoclonal antibody, PR81, recognizing the tandem repeat region of MUC1 mucin. Hybrid Hybridomics. 2003;22(3):153-8. doi: 10.1089/153685903322286566. [PubMed: 12954100].
  • 19. Soukhtanloo M, Ansari M, Paknejad M, Parizadeh MR, Rasaee MJ. Preparation and characterization of monoclonal antibody against melatonin. Hybridoma (Larchmt). 2008;27(3):205-9. doi: 10.1089/hyb.2008.0002. [PubMed: 18582215].
  • 20. Kuo MH, Allis CD. In vivo cross-linking and immunoprecipitation for studying dynamic Protein:DNA associations in a chromatin environment. Methods. 1999;19(3):425-33. doi: 10.1006/meth.1999.0879. [PubMed: 10579938].
  • 21. Weinmann AS, Farnham PJ. Identification of unknown target genes of human transcription factors using chromatin immunoprecipitation. Methods. 2002;26(1):37-47. doi: 10.1016/S1046-2023(02)00006-3. [PubMed: 12054903].
  • 22. Babaei A, Zarkesh-Esfahani SH, Gharagozloo M. Production of a recombinant anti-human CD4 single-chain variable-fragment antibody using phage display technology and its expression in Escherichia coli. J Microbiol Biotechnol. 2011;21(5):529-35. [PubMed: 21617352].
  • 23. Abad PC, Lewis J, Mian IS, Knowles DW, Sturgis J, Badve S, et al. NuMA influences higher order chromatin organization in human mammary epithelium. Mol Biol Cell. 2007;18(2):348-61. doi: 10.1091/mbc.E06-06-0551. [PubMed: 17108325].
  • 24. Yafi FA, Brimo F, Steinberg J, Aprikian AG, Tanguay S, Kassouf W. Prospective analysis of sensitivity and specificity of urinary cytology and other urinary biomarkers for bladder cancer. Urol Oncol. 2015;33(2):66 e25-31. doi: 10.1016/j.urolonc.2014.06.008. [PubMed: 25037483].
  • 25. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. 1975. J Immunol. 2005;174(5):2453-5. [PubMed: 15728446].
  • 26. Radulescu AE, Cleveland DW. NuMA after 30 years: the matrix revisited. Trends Cell Biol. 2010;20(4):214-22. doi: 10.1016/j.tcb.2010.01.003. [PubMed: 20137953].
  • 27. Bibila TA, Ranucci CS, Glazomitsky K, Buckland BC, Aunins JG. Monoclonal antibody process development using medium concentrates. Biotechnol Prog. 1994;10(1):87-96. doi: 10.1021/bp00025a011. [PubMed: 7764531].
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments